55751-60-5

Basic information

• Product Name: 2-(Cyclohexyloxy)-benzoic acid
• Synonyms: Benzoic acid, 2-(cyclohexyloxy)-
• CAS NO: 55751-60-5
• Molecular Formula: C₁₃H₁₆O₃
• Molecular Weight: 220.26434
• Mol File: 55751-60-5.mol
• Article Data: 1

Chemical Properties

• Melting Point: 83-85 °C(Solv: ethanol (64-17-5))
• Boiling Point: 369.6±15.0 °C(Predicted)
• Appearance: /
• Density: 1.168±0.06 g/cm3(Predicted)
• PKA: 3.41±0.36(Predicted)
• CAS DataBase Reference: 2-(Cyclohexyloxy)-benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(Cyclohexyloxy)-benzoic acid(55751-60-5)
• EPA Substance Registry System: 2-(Cyclohexyloxy)-benzoic acid(55751-60-5)

Safety Data

• Hazardous Substances Data: 55751-60-5(Hazardous Substances Data)

Usage

General Description

2-(Cyclohexyloxy)-benzoic acid is a chemical compound with the molecular formula C13H16O3. It is a carboxylic acid derivative with a cyclohexyloxy group attached to the benzoic acid molecule. 2-(Cyclohexyloxy)-benzoic acid is commonly used as a building block in the synthesis of various pharmaceuticals and organic compounds. It has potential applications in the field of medicine, as well as in the production of polymers and other industrial products. 2-(Cyclohexyloxy)-benzoic acid is a versatile chemical that can be modified and utilized for a wide range of purposes in organic chemistry.

Upstream product

• 92864-17-0 methyl 2-(cyclohexyloxy)benzoate 

Downstream Products

• 1078711-97-3 2-(cyclohexyloxy)-N-{(3-exo)-8-[(6-fluoro-2-naphthyl)methyl]-8-azabicyclo[3.2.1]oct-3-yl}benzamide 

Relevant articles and documents

Design and synthesis of 6-fluoro-2-naphthyl derivatives as novel CCR3 antagonists with reduced CYP2D6 inhibition

In our previous study on discovering novel types of CCR3 antagonists, we found a fluoronaphthalene derivative (1) that exhibited potent CCR3 inhibitory activity with an IC50 value of 20 nM. However, compound 1 also inhibited human cytochrome P450 2D6 (CYP2D6) with an IC50 value of 400 nM. In order to reduce its CYP2D6 inhibitory activity, we performed further systematic structural modifications on 1. In particular, we focused on reducing the number of lipophilic moieties in the biphenyl part of 1, using C log D7.4 values as the reference index of lipophilicity. This research led to the identification of N-{(3-exo)-8-[(6-fluoro-2-naphthyl)methyl]-8-azabicyclo[3.2.1]oct-3-yl}-3-(piperidin-1-ylcarbonyl)isonicotinamide 1-oxide (30) which showed comparable CCR3 inhibitory activity (IC50 = 23 nM) with much reduced CYP2D6 inhibitory activity (IC50 = 29,000 nM) compared with 1.